1-3 of 3
Roman Hájek
Close
Sort by
Journal Articles

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

Clinical Trials & Observations
Thomas Martin, Joseph Mikhael, Roman Hajek, Kihyun Kim, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, Anup George, Tatiana Konstantinova, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4506–4515.
https://doi.org/10.1182/bloodadvances.2021006713
Published: 2022
Journal Articles

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Martina Zátopková, Tereza Ševčíková, Viola Fanfani, Zuzana Chyra, Lucie Říhová, Renata Bezděková, David Žihala, Kateřina Growková, Jana Filipová, Lucie Černá, Lucie Broskevičova, Fedor Kryukov, Jiří Minařík, Jana Smejkalová, Vladimír Maisnar, Ĺubica Harvanová, Luděk Pour, Alexandra Jungova, Tereza Popková, Juli Rodriguez Bago, Anjana Anilkumar Sithara, Matouš Hrdinka, Tomáš Jelínek, Michal Šimíček, Giovanni Stracquadanio, Roman Hájek
Journal: Blood Advances
Blood Adv (2022) 6 (2): 368–372.
https://doi.org/10.1182/bloodadvances.2020003876
Published: 2022
Includes: Supplemental data
Journal Articles

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Clinical Trials & Observations
Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, Jose Banchs, Roman Hajek, John Groarke, Alexander R. Lyon, George N. Batty, Sunhee Ro, Mei Huang, Karim S. Iskander, Daniel Lenihan
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1633–1644.
https://doi.org/10.1182/bloodadvances.2017015545
Published: 2018
Includes: Supplemental data